Amendments to the Specification:

Please replace the heading on page 1, line 5, with the following heading:

1 1

BACKGROUND OF THE INVENTION

Please add the following <u>new</u> heading on page 6, line 3:

BRIEF SUMMARY OF THE INVENTION

Please add the following <u>new</u> heading and paragraphs on page 9, line 1:

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 presents the expected and observed fragment patterns for the restriction digests of Example 1a.

Figure 2 presents the observed fragment patterns for BspEl-released internal control DNA restriction digests of Example 1c.

Figure 3 presents the observed fragment patterns for the restriction digests of Example 1b.

Figure 4 presents the expected and observed TRSPA-2 hybridization patterns for pNW33 using matrix 7 (Example 2).

Figure 5 presents the expected and observed TRSPA-2 hybridization patterns for pNW33 using matrix 17 (Example 2).

DETAILED DESCRIPTION OF THE INVENTION

Please replace the paragraph on page 109, line 9, though page 110, line 35, with the following amended paragraph:

BspEI sites define the outer ends of the 140 bp and the 200 bp fragments. The full

gtta caa at attecgag cacca aga at ggctgcgcgcttgcctggtacttgacgtcgtatttgacggggtccttgag aa agt at ttall accompanies of the control of the conta actggaaca caatctg aggaat gatca aa gcaaccaacgccaacgcata ataactagtg caataccaa gacctcccaataatageacce agact t g t gata t a acctet g get c t gatat t get c eagat g gatat t g gatat t g gatat t get c gatat t get gatat t get c gatat t get g gatat t g gatat tctttatgaggatctctctgatttttcttgcgtcgagttttccggtaagacctttcggtacttcgtccacaaacacaactcctccgcgcaactttttcgcggttgttacttgactggccacgtaatccacgatctctttttccgtcatcgtctttccgtgctccaaaacaacaacaggcggcgggtccggattaccagctgcgatcaagcttatcgataccgtcgacctcgacctgcaggcatgcaagcttggcgtaatcatggtcat agctgtttcctgtgtgaaattgttatccgctcacaattccacacaacatacgagccggaagcataaagtgtaaagcctggggtgcct a at gag t gag cta act ca cat ta at t gcg t t gcg ct cact gcc cgctt t cca g t cgg gaa a acct g t cg t gcc ag ct g cat ta at ta at the contract of the contract gag gag and contract g cc g contract g cc g cat ta at the contract g cc g cat tatteggetgeggeggggtateageteacteaaaggeggtaataeggttateeacagaateaggggataaegeaggaaagaae atgtgagcaaaaggccagcaaaaggccaggaaccgtaaaaaggccgcgttgctggcgtttttccataggctccgcccctga cgagcatcacaaaaatcgacgctcaagtcagaggtggcgaaacccgacaggactataaagataccaggcgtttcccctggaa gctccctcgtgcgctctcctgttccgaccctgccgcttaccggatacctgtccgcctttctcccttcgggaagcgtggcgctttctc ccgctgcgccttatccggtaactatcgtcttgagtccaacccggtaagacacgacttatcgccactggcagcagccactggtaacaggattag cagag cgagg tat gtagg cggtg ctacagag ttcttg aagtg gtggcctaac tacggctacactag aaggacag tacggagg taggagg tacggagg tacggaggct cagtggaac gaaaact cacgtta agggatttt ggt catgagattat caaaaaggatctt cacctagat cctttta aatta aaaatgaagttttaaatcaatctaaagtatatatgagtaaacttggtctgacagttaccaatgcttaatcagtgaggcacctatctcagcgatc tgtctatttcgttcatccatagttgcctgactccccgtcgtgtagataactacgatacgggagggcttaccatctggccccagtgctg tgtt at cacte at ggtt at gg cag cact gc at a attetet tact gt cat gc cat ccg taa gat gc ttt tct gt gact gg tg ag tact caa

Appl. No. 09/914,604

Amendment dated October 17, 2003

Reply to Office action of May 21, 2003

cca a g t cattet g a gaat a g t g t except g consideration of the cons

ä e

gaactttaaaagtgctcatcattggaaaacgttcttcggggcgaaaactctcaaggatcttaccgctgttgagatccagttcgatgt

tct catgageggata catatttgaatgtatttagaaaaataaacaaataggggtt ccgcgcacatttccccgaaaagtgccacctga

cgtctaagaaaccattattatcatgacattaacctataaaaataggcgtatcacgaggccctttcgtc (SEQ ID NO: 1)

Please replace the paragraph on page 115, lines 7-13, with the following amended

paragraph:

Primers and PCR

20 µM BIO140UP

5' biotin-CGCAGCTGGTAATCCGGACGCCCGCGTCGAAGATGTT 3'

(SEQ ID NO: 2)

20 μM BIO200DOWN

5' biotin-CGCAGCTGGTAATCCGGACCCGCCGCCGTTGTTGTT 3'

(SEQ ID NO: 3)

Please replace the paragraph on page 119, lines 9-16, with the following amended

paragraph:

After digestion, 20 µl of digests 1-7 were mixed with 10 µl of 50 % glycerol AGE

loading dye and 4 µl of digests 1-7ic were mixed with 2 µl of 50 % glycerol AGE loading

Page 6 of 32

dye. Digests in loading dye were then electrophoresed on a 2.5 % MetaPhorTM agarose gel in 1x TBE. The gel was stained for 60 min in 500 ml of 1x TBE containing 50 μl of Vistra Green. The stained gel was finally imaged on a Fluorimager with the following settings: a 488 nm laser; a 570 DF 30 filter; a PMT setting of 700 V; 200 μm resolution; and low sensitivity.

1 .

Please replace the paragraph on page 121, line 6, though page 122, line 22, with the following amended paragraph:

HindIII and EcoRI sites define the outer ends of the 25 bp and the 40 bp fragments. The sequence of pNW35 (SEQ ID NO: 4) is shown below with the inserted region shown in bold type:

cgg caa caatta at a gactgg at gg ag gg at aa ag tt g cag gac cactt ct gcg ct cgg ccctt ccgg ct gg ct gg tt tat tg a gactga account considerable and the considerable and the considerable account considerable and the considerable account coctgataaatctggagccggtgagcgtgggtctcgcggtatcattgcagcactggggccagatggtaagccctcccgtatcgtagttatctacacgacggggagtcaggcaactatggatgaacgaaatagacagatcgctgagataggtgcctcactgattaagcattg actettttteegaaggtaactggetteageagagegeagataecaaatactgteettetagtgtageegtagttaggeeaceacttegggttggactcaagacgatagttaccggataaggcgcagcggtcgggctgaacggggggttcgtgcacacagcccagcttggagcgaacgacctacaccgaactgagatacctacagcgtgagctatgagaaagcgccacgcttcccgaagggagaaaggcgg a acg cgg cetttttacgg ttcctgg cettttgctgg cettttgctca catgttctttcctg cgt tatcccctg attctgtgg at aaccgt at the control of thegegeceaataegeaaaeegeeteteeeegegegttggeegatteattaatgeagetggeaegaeaggttteeegaetggaaage gtgtggaattgtgageggataacaatttcacacaggaaacagct (SEQ ID NO: 4)

Please replace the paragraph on page 123, lines 3-7, with the following amended paragraph:

Primers and PCR

U-19 mer bio primer 5' bio-GTTTTCCCAGTCACGACGT 3'

(SEQ ID NO: 5)

ICPCR(F) primer 5' TCCGGACGTCTCAGGCTAATGTT 3'

(**SEQ ID NO: 6**)

Please replace the paragraph on page 129, line 12, through page 130, line 13, with the following amended paragraph:

Oligonucleotides

BamHI short PCR primer 5' TGTAACGACACATTGCTGGATACC 3'

(**SEQ ID NO: 7**)

HindIII short PCR primer 5' ATATAACTCTCGCTCCTTGATAAC 3'

(SEQ ID NO: 8)

NcoI short PCR primer 5' AGGCGTCTGAGGCTGCGGCTATGG 3'

(**SEQ ID NO: 9**)

SpeI short PCR primer 5' AACCCGTCGCGACGAGAGTCTAAG 3'

(SEQ ID NO: 10)

AfIII short PCR primer 5' GATATACGTGATATATTTTGATTG 3'

(SEQ ID NO: 11)

BamHI adaptor 5' pGATCGGTATCCAGCAATGTGTCGTTACA 3'

(SEQ ID NO: 12)

HindIII adaptor 5' pAGCTGTTATCAAGGAGCGAGAGTTATAT 3'

(SEQ ID NO: 13)

NcoI adaptor 5' pCATGCCATAGCCGCAGCCTCAGACGCCT 3'

(SEQ ID NO: 14)

SpeI adaptor 5' pCTAGCTTAGACTCTCGTCGCGACGGGTT 3'

(SEQ ID NO: 15)

AfIII adaptor 5' pTTAACAATCAAAATATATCACGTATATC 3'

(SEQ ID NO: 16)

BamHI long PCR primer 5' TGTAACGACACATTGCTGGATACCGATCC 3'

(SEQ ID NO: 17)

HindIII long PCR primer 5' ATATAACTCTCGCTCCTTGATAACAGCTT 3'

(SEQ ID NO: 18)

Ncol long PCR primer 5' AGGCGTCTGAGGCTGCGGCTATGGCATGG 3'

(SEQ ID NO: 19)

Spel long PCR primer 5' AACCCGTCGCGACGAGAGTCTAAGCTAGT 3'

(SEQ ID NO: 20)

AfIII long PCR primer 5' GATATACGTGATATATTTTGATTGTTAAG 3'

(SEQ ID NO: 21)

Luc140down primer

5' GCGCTAGGGATCCTTACTGGGACGAAGACGAA 3'

(SEQ ID NO: 22)

Luc140up-bio primer

5' biotin-CGCAGCTGGTAATCCGGACGCCCGCGTCGAAGATGTT3'
(SEQ ID NO: 23)

Please replace the paragraph on page 138, lines 6-32, with the following amended paragraph:

Clone #1

Mutant sequence (#1M)

5'CCCGGGGGATCCTCGTTTTATTGGGCCGAGTTTTGGTCCGTAGTGCTTGGTT
AGATATGCTTAT
3'GGGCCCCCTAGGAGCAAAATAACCCGGCTCAAAACCAGGCATCACGAACC
AATCTATACGAATA

GTTCACAAAATCATCCTTGTACAGAATTC3'(SEQ ID NO: 24)
CAAGTGTTTTAGTAGGAACATGTCTTAAG5'

Control sequence (#1C)

5'CCCGGGGGATCCTCGTTTTATTGGGCCGAGTTTTGGTCCGTAGTGCATGGTT
AGATATGCTTAT
3'GGGCCCCCTAGGAGCAAAATAACCCGGCTCAAAACCAGGCATCACGTACCA
ATCTATACGAATA

GTTCACAAAATCATCCTTGTACAGAATTC3' (SEQ ID NO: 25)

CAAGTGTTTTAGTAGGAACATGTCTTAAG5'

Clone #7

Control sequence (#7C)

5'CCCGGGTGTACACAAAAGTTTACCTGAAGAACGTGGGGGGTCGTGCCTGGT CTTGCGTCACCTG 3'GGGCCCACATGTGTTTTCAAATGGACTTCTTGCACCCCCCAGCACGGACCA GAACGCAGTGGAC

GTCTCAGGAGAGGGTCCCCATGGGAATTC3'(SEQ ID NO: 26)
CAGAGTCCTCTCCCAGGGGTACCCTTAAG5'

Please replace the paragraph on page 139, lines 6-8, with the following amended paragraph:

Oligonucleotides

BIOUPST2 5' bio-CTACTGATCGGATCCCCG 3' (SEQ ID NO: 27)
BIODOWN3 5' bio-AAACGACGGCCAGTGAAT 3' (SEQ ID NO: 28)

Please replace the paragraph on page 141, lines 4-7, with the following amended paragraph:

Oligonucleotides

BIOUPST2 5' bio-CTACTGATCGGATCCCCG 3' (SEQ ID NO: 29)

DOWN3 5' bio-AAACGACGGCCAGTGAAT 3' (SEQ ID NO: 30)

Please replace the paragraph on page 145, lines 4-8, with the following amended paragraph:

Oligonucleotides

#1 probe oligo 5' GGCCGAGTTTTGGTCCGTAG 3' (SEQ ID NO: 31)

#7 probe oligo 5' GTCTTGCGTCACCTGGTCTCAG 3' (SEQ ID NO: 32)

At the end of the written description, before the claims, please delete the previously submitted "Sequence Listing" and insert the revised "Sequence Listing" attached hereto.